EIM
HRTX icon

Essex Investment Management’s Heron Therapeutics HRTX Stock Holding History

Essex Investment Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-695,993
Closed -$2.44M – 313
2024
Q2 		$2.44M Buy
+695,993
New +$2.14M 0.46% 85
2016
Q2 		– Sell
-16,100
Closed -$306K – 326
2016
Q1 		$306K Buy
+16,100
New +$318K 0.05% 283

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Essex Investment Management's HRTX Position: Q3 2024 in Review

Essex Investment Management sold out of Heron Therapeutics (HRTX) in Q3 2024, closing a stake of 695,993 shares — an estimated $2.44M sold.

Essex Investment Management first reported a position in HRTX in Q1 2016 and held it in 2 quarters. The position peaked at $2.44M in Q2 2024. 173 funds tracked by Wall St. Rank hold HRTX as of Q3 2024.

  • Essex Investment Management reported no remaining Heron Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Essex Investment Management sold 695,993 Heron Therapeutics shares in Q3 2024, an estimated $2.44M.
  • Essex Investment Management first reported a position in Heron Therapeutics in Q1 2016 and held it in 2 quarters.
  • Essex Investment Management's Heron Therapeutics position peaked at $2.44M in Q2 2024.
  • 173 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2024.

Based on Essex Investment Management's 13F filing for Q3 2024, filed 10 Oct 2024.